Back to News

Sep 04, 2015

Geisinger Health Plan Establishes Relationship with CleanSlate Addition Treatment Centers

DANVILLE, PA AND NORTHAMPTON, MA – As the number of Pennsylvanians suffering from opioid dependence continues to increase, access to affordable, effective care remains limited for many. In order to enhance access to high-quality addiction treatment for GHP members, Geisinger Health Plan (GHP) and CleanSlate Addiction Treatment Centers announced a collaborative relationship today.CleanSlate, based in Massachusetts, provides award-winning, outpatient, medication assisted treatment and related therapies for patients who have addiction and associated disorders using the highest quality, evidence based practices.

CleanSlate will initially offer two facilities in Pennsylvania. The first two Pennsylvania offices will be located at 189 E. Market Street, Wilkes-Barre, PA and 1020 W. Lackawanna Ave., Scranton, PA. The Wilkes-Barre location will begin operations in September, followed in October by the Scranton location. Susquehanna is an additional area under consideration for potential expansion.

One study suggests that the costs of an individual suffering from addiction not getting treatment—in terms of policing, incarceration, absenteeism, and other impacts on society—exceeds $200,000 over a two-year period. In addition:

  • Nationwide, 100 deaths occur each day from overdoses involving narcotic pain relievers.
  • Opioid-related overdoses now kill more people between the ages of 25 and 64 every year than motor vehicle accidents.
  • Prescription painkillers claim more lives than heroin and cocaine combined.
  • The death toll from opioid overdoses has more than tripled in the last decade.
  • In 2012, 669,000 people used heroin in the U.S., up from 373,000 users in 2007.
  • There was also a nearly two-fold increase in the number of people using heroin for the first time in 2012 compared to 2006 (156,000 in 2012 versus 90,000 in 2006).

    “There is currently a significant shortage of quality care for opioid addiction treatment in Pennsylvania. We have been working with CleanSlate Centers since late 2014 to discuss ways they can help our members receive the care they need to help them through the challenges associated with addiction and recovery,” says Kathleen Fierros, vice president of provider network innovations. “We were impressed by CleanSlate’s compassionate and coordinated approach to care; an approach very akin to our own at GHP.

    “We are thrilled to be working with Geisinger,” says Joan Erwin, Senior Vice President of Operations at CleanSlate. “They clearly understand the severity of the epidemic, and have worked expeditiously to ensure that their members have access to high quality, evidence-based treatment. By working together, we will be able to make a huge difference in the lives of hundreds of patients.”
  • About CleanSlate Centers


    CleanSlate was founded in 2009 in response to the growing opioid epidemic facing the country. A network of outpatient addiction treatment centers, CleanSlate provides compassionate, effective, medication-assisted treatment and related therapies for patients who have addiction and associated disorders using the highest quality, evidence-based practices. In recognition of their innovation and effectiveness, CleanSlate’s doctor-led treatment programs received the inaugural 2012 Science and Service Award for Office-based Opioid Treatment by the federal Substance Abuse and Mental Health Service Administration (SAMHSA). In 2014, CleanSlate partnered with Apple Tree Partners, a growth equity fund, to help expand efforts geographically and increase access to care in underserved communities with demonstrated need.

    About Geisinger Health Plan

    Geisinger Health Plan, begun in 1985, is headquartered in Danville, Pennsylvania. GHP is the #1 ranked commercial and Medicare health plans in Pennsylvania. Nationally, GHP is ranked #12 among commercial health plans and #10 among Medicare health plans according to the National Committee for Quality Assurance (NCQA) Health Insurance Plan Rankings 2014-2015. The plan serves more than 510,000 members in Pennsylvania, Delaware, Maine, New Jersey and West Virginia. Coverage is available for businesses of all sizes, individuals and families, Medicare beneficiaries and Children’s Health Insurance Program and medical assistance recipients. For more information, please visit TheHealthPlan.com.

    More News

    Mar 09, 2017

    Fight Colorectal Cancer Partners With Cure Forward

    Read more

    Feb 20, 2017

    CleanSlate Centers' Officials Join District Attorney's Addiction Task Force

    Read more

    Feb 20, 2017

    Indiana Medicaid Members Gain Access to Leading Addiction Treatment

    Read more

    Feb 13, 2017

    Fast Company Honors Braeburn as a Top Ten Most Innovative Company in Biotech

    Read more

    Jan 13, 2017

    Braeburn Pharmaceuticals’ Probuphine® Implant Receives J-Code

    Read more

    Jan 04, 2017

    Opioid Addiction Treatment Leader CleanSlate Launches Center in Fort Wayne

    Read more

    Dec 19, 2016

    CleanSlate Centers Adds Executive to East Division Leadership

    Read more

    Dec 12, 2016

    National Opioid Addiction Treatment Leader CleanSlate Launches Center in Elkhart

    Read more

    Nov 21, 2016

    Braeburn and CEO Behshad Sheldon Win Stevie Awards

    Read more

    Nov 17, 2016

    Syntimmune Announces Appointment of David De Graaf, Ph.D., as CEO

    Read more

    Nov 14, 2016

    Braeburn Pharmaceuticals and Camurus Announce Positive Top-line Phase 3 Results

    Read more

    Oct 31, 2016

    Opioid Addiction Treatment Leader CleanSlate Launches Center in East Boston

    Read more

    Oct 27, 2016

    ​ Probuphine® Wins Popular Science’s “Best of What’s New” Award

    Read more

    Oct 24, 2016

    Braeburn Pharmaceuticals and Camurus Expand Collaboration and License Agreement

    Read more

    Oct 21, 2016

    Braeburn and Camurus announce the presentation of new data

    Read more

    Oct 04, 2016

    OPTUM, CLEANSLATE TO EXPAND ACCESS TO OPIOID ADDICTION TREATMENT FOR MEMBERS

    Read more

    Oct 03, 2016

    Opioid Addiction Treatment Leader CleanSlate Launches Center in Merrillville

    Read more

    Sep 30, 2016

    Braeburn and Camurus Enroll First Patients in a Phase 3 Efficacy Trial

    Read more

    Sep 22, 2016

    Cure Forward Names Consumer Healthcare and IT Veteran Frank Ingari as CEO

    Read more

    Sep 06, 2016

    ROX Medical Raises $40M Financing

    Read more

    Aug 30, 2016

    Cure Forward Stresses Patient Data Access as Trial Matching Service Matures

    Read more

    Aug 27, 2016

    HeartWare Receives FDA Approval To Enroll Supplemental Patient Cohort In Trial

    Read more

    Aug 23, 2016

    Medtronic Completes Acquisition of HeartWare International

    Read more

    Aug 15, 2016

    National Opioid Addiction Treatment Leader CleanSlate Opens Center in Anderson

    Read more

    Aug 02, 2016

    Cure Forward Selects Personal Genome Diagnostics

    Read more

    Jul 29, 2016

    VytronUS, Inc. Raises $49 Million in Series C Financing

    Read more

    Jul 29, 2016

    Apple Tree Bankrolls Johnson & Johnson Spinout Tusker Medical

    Read more

    Jul 20, 2016

    Anthony Belott joins CleanSlate Centers as Chief Development Officer

    Read more

    Jul 19, 2016

    Braeburn Pharmaceuticals Announces Probuphine Data Published

    Read more

    Jul 06, 2016

    High-Tech Healthcare Helps Eliminate Unnecessary Hospital Visits

    Read more

    Jun 28, 2016

    Cure Forward Announces First Trial Recruitment Collaboration

    Read more

    Jun 27, 2016

    Medtronic to Expand Portfolio with Acquisition of HeartWare International

    Read more

    Jun 13, 2016

    CleanSlate Centers names Gregory C. Marotta President & CEO

    Read more

    Jun 08, 2016

    CleanSlate, a Massachusetts based addiction treatment center, expands nationally

    Read more

    May 26, 2016

    FDA approves first buprenorphine implant for treatment of opioid dependence

    Read more

    Apr 20, 2016

    Dermatology Services Company QualDerm Unveils $31.8M Growth Investment

    Read more

    Mar 22, 2016

    Syntimmune Secures Second Tranche of $26 Million Series A Financing

    Read more

    Feb 22, 2016

    Braeburn and Camurus Announce Initiation of a Phase 2 Study

    Read more

    Feb 17, 2016

    Corvidia Therapeutics Raises $26M in a Series A Financing

    Read more

    Feb 01, 2016

    Braeburn Pharmaceuticals and Knight Therapeutics Announce

    Read more

    Jan 14, 2016

    Titan Pharmaceuticals and Braeburn Pharmaceuticals Announce FDA Advisory

    Read more

    Dec 15, 2015

    Braeburn Pharmaceuticals and Camurus Announces Start of Phase 3 Trial

    Read more

    Dec 09, 2015

    Titan Pharmaceuticals and Braeburn Pharmaceuticals Announce Date of FDA Review

    Read more

    Nov 10, 2015

    Tokai Pharmaceuticals Reports Third Quarter 2015 Financial Results

    Read more

    Nov 09, 2015

    CleanSlate Launches STAT Campaign for Physician Awareness of PA Opioid Epidemic

    Read more

    Nov 04, 2015

    FDA Grants Fast Track Designation for Development of CAM2038

    Read more

    Oct 01, 2015

    Pharmatech and Cure Forward to Accelerate Oncology Clinical Trial Enrollment

    Read more

    Sep 28, 2015

    FDA Accepts Braeburn’s Resubmission of Probuphine NDA for Review

    Read more

    Sep 22, 2015

    Cure Forward Launches Precision Medicine Engagement Platform for Cancer Patients

    Read more

    Sep 20, 2015

    Paul L. Chabot Joins CleanSlate Centers as the New CIO

    Read more

    Sep 17, 2015

    Braeburn Pharmaceuticals Commends HHS Secretary Burwell

    Read more

    Sep 14, 2015

    Patrick J. Murphy Joins CleanSlate Centers as the New Chief Financial Officer

    Read more

    Sep 04, 2015

    Geisinger Health Plan Establishes Relationship with CleanSlate Centers

    Read more

    Aug 12, 2015

    Tokai Pharmaceuticals Reports Second Quarter 2015 Results

    Read more

    Jul 30, 2015

    Abbott to Broaden Foundation in Structural Heart Therapies

    Read more

    Jun 24, 2015

    Tokai Announces Initiation of Phase 3 ARMOR3-SV Trial of Galeterone

    Read more

    Jun 23, 2015

    Gregory C. Marotta Joins CleanSlate Centers as the New Chief Operating Officer

    Read more

    Jun 18, 2015

    Cure Forward Receives $15 Million in Series A Financing

    Read more

    Jun 08, 2015

    Braeburn Reports Positive Results From Phase 3 Study

    Read more

    Jun 01, 2015

    Patrick J Kennedy Accepts Seat on Board of Directors at CleanSlate Centers

    Read more

    May 12, 2015

    Tokai Pharmaceuticals Reports First Quarter 2015 Financial Results

    Read more

    Apr 14, 2015

    Tendyne Announces First Patient Enrolled in US Trial

    Read more

    Apr 09, 2015

    Tendyne Raises $25 Million in Series C

    Read more

    Apr 06, 2015

    VytronUS, Inc. Attracts Industry Veteran John Pavlidis as New President and CEO

    Read more

    Mar 12, 2015

    Tokai Reports Fourth Quarter and Full Year 2014 Financial Results

    Read more

    Feb 12, 2015

    Aileron Therapeutics Initiates Phase 1 Cancer Study of ALRN-6924

    Read more

    Dec 15, 2014

    The Tendyne TMVI system was successfully implanted in the first patient

    Read more

    Dec 02, 2014

    Tendyne Announces Successful First Human Implants of TMVI

    Read more

    Nov 19, 2014

    Tokai Pharmaceuticals Presents Updated Interim Galeterone ARMOR2 Data

    Read more

    Nov 10, 2014

    Tokai Pharmaceuticals Reports Third Quarter 2014 Financial Results

    Read more

    Oct 29, 2014

    ​VytronUS, Inc. Raises $31.6 Million in Series B

    Read more

    Oct 29, 2014

    Aileron Therapeutics Secures $33 Million in Series E

    Read more

    Sep 24, 2014

    Braeburn Pharmaceuticals’ Probuphine® Study Hits Enrollment Milestone

    Read more

    Sep 23, 2014

    Tokai Pharmaceuticals Announces Closing of Initial Public Offering

    Read more

    Jun 02, 2014

    Tokai Pharmaceuticals Presents New Clinical Data for Galeterone

    Read more

    May 16, 2014

    Updated Phase 2 Clinical Data on Tokai Pharmaceuticals’ Galeterone

    Read more

    Mar 07, 2014

    Titan Announces Agreement in Principle for Probuphine Clinical Study

    Read more

    Feb 03, 2014

    Tokai's Reformulated Galeterone Demonstrates Robust PSA Reductions

    Read more

    Jan 13, 2014

    New Phase 2 Clinical Data on Tokai Pharmaceuticals’ Galeterone

    Read more

    Nov 18, 2013

    Aileron Therapeutics has secured $30 million in Series E equity financing

    Read more

    Nov 15, 2013

    Titan Pharmaceuticals Announces $5 Million Equity Investment

    Read more

    Sep 26, 2013

    Frank E. Young, Former FDA Commissioner, Joins Braeburn Pharmaceuticals as EVP

    Read more

    Aug 15, 2013

    Aileron Therapeutics Publishes Data

    Read more

    Aug 13, 2013

    Titan Announces Publication of Phase 3 Probuphine Data in Additiction

    Read more

    Aug 09, 2013

    HeartWare Presentation At The Canaccord Genuity 2013 Annual Growth Conference

    Read more

    Aug 08, 2013

    HeartWare International Reports $50.8 Million In Second Quarter 2013 Revenue

    Read more

    Jun 17, 2013

    HeartWare Receives Conditional Approval From FDA

    Read more

    May 15, 2013

    Tokai Pharmaceuticals Announces $35.5 Million Series E Financing

    Read more

    May 07, 2013

    Aileron Successfully Completes First-Ever Stapled Peptide Clinical Trial

    Read more

    Apr 29, 2013

    HeartWare International Reports $49.2 Million In First Quarter 2013 Revenue

    Read more

    Apr 10, 2013

    Aileron Therapeutics Presents New Preclinical Data on Stapled Peptide

    Read more

    Apr 04, 2013

    Tokai Announces Presentation of Galeterone Mechanism of Action Data

    Read more

    Mar 28, 2013

    Tokai Pharmaceuticals Announces Appointment of Jodie Morrison as CEO

    Read more

    Mar 22, 2013

    Titan Announces FDA Advisory Committee Recommends Approval of Probuphine®

    Read more

    Mar 14, 2013

    Titan announces date of FDA Advisory Committee Review of PROBUPHINE®

    Read more

    Mar 12, 2013

    HeartWare Announces Pricing of Public Offering of Common Stock

    Read more

    Mar 04, 2013

    Tokai to Present Data on Galeterone in Advanced Prostate Cancer

    Read more

    Jan 14, 2013

    Aileron Secures $12 Million for First-Ever Stapled Peptide Clinical Trial

    Read more

    Jan 07, 2013

    HeartWare International Announces Preliminary Fourth Quarter 2012 Revenues

    Read more

    Jan 02, 2013

    Probuphine® Receives FDA Priority Review Designation

    Read more

    Dec 17, 2012

    Titan Licenses Exclusive Probuphine® Commercialization Rights in U.S. & Canada

    Read more

    Dec 13, 2012

    Tokai Pharmaceuticals Doses First Patient in a Phase 2 Study of Galeterone

    Read more

    Nov 20, 2012

    HeartWare Receives FDA Approval for HeartWare Ventricular Assist System

    Read more

    Nov 09, 2012

    HeartWare Reports Third Quarter 2012 Results

    Read more

    Aug 07, 2012

    HeartWare Reports Second Quarter 2012 Results

    Read more

    Aug 02, 2012

    HeartWare Completes Acquisition Of World Heart Corporation

    Read more

    Jun 12, 2012

    Tokai Pharmaceuticals’ Galeterone Receives Fast Track Designation From the FDA

    Read more

    Apr 25, 2012

    FDA Advisory Committee Votes in Favor of HeartWare® Ventricular Assist System

    Read more

    Apr 02, 2012

    Positive Phase 1 data presented

    Read more

    Mar 29, 2012

    HeartWare International Expands Intellectual Property and Technology Portfolio

    Read more

    Mar 14, 2012

    10 Top Next-Gen Biotech Platforms

    Read more

    Feb 16, 2012

    HeartWare International Reports Fourth Quarter 2011 Revenues of $23.1 Million

    Read more

    Nov 17, 2011

    Aileron expands stapled peptide drug collaboration with Roche

    Read more

    Sep 20, 2011

    Tokai Pharmaceuticals Raises $23 Million in Funding

    Read more

    Sep 20, 2011

    Tokai Snaps Up $23M From Novartis and Apple Tree

    Read more

    Sep 20, 2011

    Tokai lands new CEO, $23M venture round for PhIIb cancer study

    Read more

    Jun 16, 2011

    FDA Grants Accelerated Approval of ISTODAX(R)

    Read more

    May 05, 2011

    HeartWare International Reports First Quarter 2011 Revenues of $18.0 Million

    Read more

    Apr 15, 2011

    HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial

    Read more

    Mar 24, 2011

    HeartWare International Receives Approval From the TGA in Australia

    Read more

    Feb 28, 2011

    FDA Grants Priority Review For ISTODAX(R) sNDA

    Read more

    Feb 24, 2011

    HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million

    Read more

    Jan 24, 2011

    HeartWare Receives Third Patient Allotment From FDA

    Read more

    Dec 28, 2010

    HeartWare Files PMA Application for FDA Approval

    Read more

    Dec 15, 2010

    HeartWare Announces Completion of Concurrent Public Offerings

    Read more

    Dec 10, 2010

    HeartWare Announces Pricing of Concurrent Public Offerings

    Read more

    Dec 09, 2010

    HeartWare International, Inc. Announces Concurrent Public Offerings

    Read more

    Dec 05, 2010

    New Clinical Data Evaluating ISTODAX(R) in Pivotal Open-Label Phase II Study

    Read more

    Nov 14, 2010

    HeartWare 5-Ounce Pump Extends Lives in Heart Failure Patients

    Read more

    Nov 14, 2010

    HeartWare Achieves Primary Endpoint

    Read more

    Aug 24, 2010

    Roche Backs New Method for Drug Delivery to Cells

    Read more

    Aug 24, 2010

    Roche Enters $1.1B Deal With Aileron To Produce New Drugs

    Read more

    Aug 01, 2010

    Stapled Peptides on the cover of the August issue of Nature Chemical Biology

    Read more

    Jun 24, 2010

    HeartWare Announces Board Succession

    Read more

    Jun 14, 2010

    HeartWare Receives Conditional FDA Approval

    Read more

    Apr 23, 2010

    HeartWare Data From First 100 Patients

    Read more

    Apr 07, 2010

    HeartWare Receives FDA Approval of Continued Access Protocol

    Read more

    Feb 22, 2010

    HeartWare Announces Early Conclusion of Enrollment

    Read more

    Feb 02, 2010

    HeartWare Announces Completion of Public Offering of Common Stock

    Read more

    Jan 26, 2010

    HeartWare Announces Commencement of Public Offering of Common Stock

    Read more

    Dec 07, 2009

    Celgene to Acquire Gloucester Pharmaceuticals

    Read more

    Nov 27, 2009

    Tokai eyes novel weapon to battle prostate cancer

    Read more

    Nov 11, 2009

    Aileron Therapeutics Collaborators Publish In Vivo Research in Nature

    Read more

    Nov 05, 2009

    FDA Approves Gloucester's ISTODAX® for Cutaneous T-cell Lymphoma

    Read more

    Oct 10, 2009

    Tokai Pharmaceuticals Initiates ARMOR Program for TOK-001

    Read more

    Sep 02, 2009

    FDA Advisory Committee Recommends Gloucester's Romidepsin for Approval

    Read more

    Aug 25, 2009

    Gloucester raises $29 million

    Read more

    Aug 21, 2009

    HeartWare International Surpasses 50 Implants In The US

    Read more

    Aug 17, 2009

    HeartWare International, Inc. Closes US$60 Million Financing

    Read more

    Jun 08, 2009

    Aileron Therapeutics Closes $40M Financing To Advance Stapled Peptide Platform

    Read more

    Jun 01, 2009

    “Emerging Drug Developer” Tokai Pharmaceuticals

    Read more

    Oct 22, 2008

    Aileron Advances First Stapled Peptide Drug Candidate

    Read more